Indazoles

Kronos Bio Announces Participation in Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 26, 2021
Enzymes, Tyrosine kinase inhibitors, Chemical compounds, Entospletinib, Indazoles, Morpholines, Tyrosine kinase receptors, Tyrosine kinases, Branches of biology, CD135, Tyrosine-protein kinase SYK, Acute myeloid leukemia

The fireside chats will be webcast live from the Investors & Media section of the companys website at www.kronosbio.com .

Key Points: 
  • The fireside chats will be webcast live from the Investors & Media section of the companys website at www.kronosbio.com .
  • Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.
  • Kronos Bio is developing a portfolio of spleen tyrosine kinase (SYK) inhibitors, entospletinib (ENTO) and lanraplenib (LANRA), for the treatment of NPM1-mutated and FLT3-mutated acute myeloid leukemia (AML).
  • Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.

Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day

Retrieved on: 
Tuesday, May 11, 2021
Branches of biology, Entospletinib, Indazoles, Morpholines, Tyrosine-protein kinase SYK, Acute myeloid leukemia, NPM1, Myc, Tyrosine kinase

\xe2\x80\x9cWe recently showcased progress with our CDK9 program at the AACR annual meeting in April, where we presented preclinical data indicating that KB-0742 could have utility in the treatment of MYC-amplified cancers.

Key Points: 
  • \xe2\x80\x9cWe recently showcased progress with our CDK9 program at the AACR annual meeting in April, where we presented preclinical data indicating that KB-0742 could have utility in the treatment of MYC-amplified cancers.
  • We look forward to sharing more about our development plans for this compound at our research and development day.\xe2\x80\x9d\nDr.
  • The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth.
  • Kronos Bio\xe2\x80\x99s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML).

Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference

Retrieved on: 
Thursday, May 6, 2021
Entospletinib, Indazoles, Morpholines, Tyrosine-protein kinase SYK, Enzymes, Acute myeloid leukemia, Tyrosine kinase, NPM1, Protein kinase inhibitors

A replay of the webcast will be archived and available for one month following the event.\nKronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.

Key Points: 
  • A replay of the webcast will be archived and available for one month following the event.\nKronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.
  • The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth.
  • Kronos Bio\xe2\x80\x99s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML).
  • For more information, visit www.kronosbio.com or follow the company on LinkedIn .\n'

Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)

Retrieved on: 
Thursday, March 4, 2021
Chemical compounds, Acute myeloid leukemia, Entospletinib, Indazoles, Morpholines, Branches of biology, Organic compounds, Leukemia, Tyrosine-protein kinase SYK, 7+3, NPM1, HOXA9

Even with current therapies, about half of patients with newly diagnosed NPM1-mutated AML will die from the disease within five years.

Key Points: 
  • Even with current therapies, about half of patients with newly diagnosed NPM1-mutated AML will die from the disease within five years.
  • Kronos Bios lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML).
  • Results of a Phase 1b/2 study of entospletinib (GS-9973) monotherapy and in combination with induction chemotherapy in newly diagnosed patients with acute myeloid leukemia.
  • Entospletinib in combination with induction chemotherapy in previously untreated acute myeloid leukemia: response and predictive significance of HOXA9 and MEIS1 expression.

Asana BioSciences’ Gusacitinib Granted FDA Fast-Track Designation for Moderate-to-Severe Chronic Hand Eczema

Retrieved on: 
Wednesday, February 3, 2021
Research, FDA, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Enzymes, Tyrosine-protein kinase SYK, Tyrosine kinase, Jak, Drugs, Tyrosine kinase inhibitors, Orphan drugs, Protein kinase inhibitors, Indazoles, Cerdulatinib, Janus kinase inhibitor

Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to Asanas gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), for the treatment of moderate-to-severe Chronic Hand Eczema (CHE).

Key Points: 
  • Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to Asanas gusacitinib (ASN002), an investigational oral, dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), for the treatment of moderate-to-severe Chronic Hand Eczema (CHE).
  • Patients with CHE suffer greatly from this disease, which limits their ability to work and perform activities of daily living.
  • There are no approved treatments for patients suffering from CHE in the U.S. and in many other major markets.
  • We are pleased that the FDA has granted Fast-Track designation to gusacitinib.

CHOP Researchers Find NTRK Fusions More Common than Expected in Pediatric Tumors

Retrieved on: 
Friday, January 15, 2021
Chemical compounds, Orphan drugs, Drugs, Organic compounds, Breakthrough therapy, Entrectinib, Indazoles, Piperazines, Larotrectinib, ROS1

The researchers found that NTRK fusions are more common in pediatric tumors and also involve a wider range of tumors than adult cancers, information that could help prioritize screening for NTRK fusions in pediatric cancer patients who might benefit from treatment with TRK inhibitors.

Key Points: 
  • The researchers found that NTRK fusions are more common in pediatric tumors and also involve a wider range of tumors than adult cancers, information that could help prioritize screening for NTRK fusions in pediatric cancer patients who might benefit from treatment with TRK inhibitors.
  • "With the recent FDA approval of larotrectinib and entrectinib for the treatment of adult and pediatric NTRK-positive, unresectable solid tumors, identification of these fusions directly impacts patient care."
  • The researchers identified NTRK fusions in 29 tumors from 27 patients, with a positive yield of 2.22% for all tumors and 3.08% for solid tumors.
  • "Our experience highlights the clinical utility of screening NTRK fusions for all pediatric tumors."

Kronos Bio Announces Participation in Upcoming Investor Conferences

Retrieved on: 
Monday, November 23, 2020
Tyrosine kinase inhibitors, Entospletinib, Indazoles, Morpholines, Tyrosine kinases, Tyrosine-protein kinase SYK, Enzymes, Acute myeloid leukemia, Tyrosine kinase, NPM1

The fireside chats will be available from the Investors & Media section of the companys website at www.kronosbio.com .

Key Points: 
  • The fireside chats will be available from the Investors & Media section of the companys website at www.kronosbio.com .
  • Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing therapies that seek to transform the lives of those affected by cancer.
  • Kronos Bios lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML).
  • Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.

Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results

Retrieved on: 
Wednesday, November 18, 2020
Tyrosine kinase inhibitors, Chemical compounds, Entospletinib, Indazoles, Morpholines, Tyrosine kinases, Enzymes, Heterocyclic compounds, Tyrosine-protein kinase SYK, Acute myeloid leukemia, NPM1, Gilead Sciences

Kronos Bio experienced transformational growth in 2020.

Key Points: 
  • Kronos Bio experienced transformational growth in 2020.
  • In July 2020, a cquired Gilead Sciences portfolio of spleen tyrosine kinase (SYK) inhibitors, including entospletinib, which Kronos Bio is developing as a frontline treatment for patients with NPM1-mutated acute myeloid leukemia (AML).
  • These results were previously presented at the American Association for Cancer Research Virtual Annual Meeting II in June 2020.
  • Net Loss: Net loss was $39.7 million, or $6.48 per basic and diluted share, for the quarter ended September 30, 2020.

Exploratory Analysis Reports Efficacy and Safety of BAVENCIO® (avelumab) Over Three Years in Previously Treated Metastatic Merkel Cell Carcinoma

Retrieved on: 
Tuesday, October 22, 2019
Clinical medicine, Medicine, Cancer, Cancer treatments, Pyridines, Kidney cancer, Axitinib, Indazoles, Thioethers, Renal cell carcinoma, Avelumab, Chemotherapy

"Historically, chemotherapy has been the only treatment for advanced Merkel cell carcinoma, with responses lasting for less than one year.

Key Points: 
  • "Historically, chemotherapy has been the only treatment for advanced Merkel cell carcinoma, with responses lasting for less than one year.
  • Withhold BAVENCIO for moderate (Grade 2) and permanently discontinue for severe (Grade 3), life-threatening (Grade 4), or recurrent moderate (Grade 2) pneumonitis.
  • Fatal adverse reactions occurred in 1.8% of patients with advanced renal cell carcinoma (RCC) receiving BAVENCIO in combination with axitinib.
  • Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.

Aravive Announces Publication of AVB-500 Nonclinical Study in Treatment-Resistant ccRCC Animal Models in Cancer Research

Retrieved on: 
Friday, October 18, 2019
Chemical compounds, Organic compounds, Indazoles, Angiology, Tyrosine kinase receptors, Kidney cancer, Renal cell carcinoma, Proteins, Pazopanib, GAS6, AXL receptor tyrosine kinase, Angiogenesis

The study, entitled S100A10 is a critical mediator of GAS6/AXL-induced angiogenesis in renal cell carcinoma was published in the October edition of the peer-reviewed journal Cancer Research.

Key Points: 
  • The study, entitled S100A10 is a critical mediator of GAS6/AXL-induced angiogenesis in renal cell carcinoma was published in the October edition of the peer-reviewed journal Cancer Research.
  • The research supports our plans to develop AVB-500 in ccRCC, and we remain on track to initiate clinical development in 4Q2019/1Q2020.
  • Key conclusions of the study include:
    Genetic inhibition of AXL in ccRCC cells reduces tumor vessel density and growth.
  • GAS6 inhibition by AVB-500 synergizes with pazopanib and axitinib to reduce ccRCC patient-derived xenograft growth and vessel density.